Evaluation of in vivo labelled dendritic cell migration in cancer patients

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Ridolfi, Ruggero ^a   Riccobon, Angela ^a   Galassi, Riccardo ^a   Giorgetti, Gianluigi ^a   Petrini, Massimiliano ^a   Fiammenghi, Laura ^b   Stefanelli, Monica ^b   Ridolfi, Laura ^a   Moretti, Andrea ^a   Migliori, Giuseppe ^a   Fiorentini, Giuseppe ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL INDIUM IN 111; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INTERFERON; KEYHOLE LIMPET HEMOCYANIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL MATURATION; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; INOCULATION; ISOTOPE LABELING; KIDNEY CARCINOMA; LYMPH NODE; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; VACCINATION;

EID: 18144403570     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-2-27     Document Type: Article

References (35)

1. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001, 94:459-473.
2. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M: Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003, 21:135-142.
3. Reinhard G, Marten A, Kiske SM, Feil F, Beiber T, Schmidt-Wolf IG: Generation of dendritic cell-based vaccines for cancer. Br J Cancer 2002, 86:1529-1533.
4. Schuler G, Schuler-Turner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15:138-147.
5. Lanzavecchia A, Sallusto F: Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
6. Mellman I, Steinman RM: Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106: 255-258.
7. Lanzavecchia A, Sallusto F: The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001, 13:291-298.
8. Romani N, Ratzinger G, Pfaller K, Salvenmoser W, Stossel H, Koch F, Stoitzner P: Migration of dendritic cells into lymphatics. The Langerhans cell example: routes, regulation and relevance. Int Rev Cytol 2001, 207:237-270.
9. Randolph GJ: Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol 2001, 13:267-274.
10. Steinman RM, Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519-1526.
11. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-253.
12. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:659-660.
13. Maldonado-Lopez R, Moser M: Dendritic cell subsets and regulation of Th1/Th2 responses. Semin Immunol 2001, 13:275-282.
14. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH: A comparison of two types of dendritic cells as adjuvants for the induction of melanoma specific T-cell responses in humans following intranodal injection. Int J Cancer 2001, 93:243-251.
15. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001, 193:233-238.
16. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G: Rapid induction of tumor-specific type I T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002, 195:1279-1288.
17. 99Tc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Md Imaging 2003, 30:440-447.
18. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, De Boer AJ, Punt CJ, Figdor CG, Adema GJ: Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999, 59:3340-3345.
19. Stoll S, Delon J, Brotz TM, Germani RM: Dynamic imaging of T cell-dendriitc cell interactions in lymph nodes. Science 2002, 296:1873-1876.
20. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK: Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999, 59:56-58.
21. Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A: Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999, 48: 118-122.
22. De Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG: Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002, 25:429-438.
23. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, Aderna GJ, Punt CJ, Figdot CG: Effective migration of antigenpulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003, 63:12-17.
24. Peters AM: Granulocyte kinetics and methods of evaluating cell performance. Nucl Med Commun 1988, 9:687-692.
25. Costa DC, Lui D, Ell PJ: White cells radiolabelled with 111In and 99Tcm - a study of relative sensitivity and in vivo viability. Nucl Med Commun 1988, 9:725-731.
26. McAfee JG, Subramanian G, Gagne G: Technique of leukocyte harvesting and labelling: problems and perspectives. Semin Nucl Med 1984, 14:83-106.
27. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995, 182:389-400.
28. Fong L, Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000, 18:245-273.
29. Foss FM: Immunologic mechanisms of antitumor activity. Semin Oncol 2002, 29(3 Suppl 7):5-11.
30. McIlroy D, Gregoire M: Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 2003, 52:583-591.
31. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27:3135-3142.
32. Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E: Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002, 100:1362-1372.
33. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M: Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002, 100:1354-1361.
34. Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML: Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998, 161:2804-2809.
35. Barrat-Boyes SM, Watkins SC, Finn OJ: In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol 1997, 158:4543-4547.